CoChat
Sign Up
Cited by 293Renin-Angiotensin System StudiesDiabetes, Cardiovascular Risks, and LipoproteinsBlood Pressure and Hypertension Studies

The DOI matches its Crossref record; 222 of the 222 references it cites were found in a registry or an index.

Prevention of Type 2 Diabetes Mellitus Through Inhibition of the Renin-Angiotensin System

Scheen, Andr?? J·2004·Drugs
DOI 10.2165/00003495-200464220-00004
Open this paper in CoChat — free account

Abstract

Type 2 diabetes mellitus is becoming a major health problem associated with excess morbidity and mortality. As the prevalence of type 2 diabetes is rapidly increasing, prevention of the disease should be considered as a key objective in the near future. Besides lifestyle changes, various pharmacological treatments have proven their efficacy in placebo-controlled clinical trials, including antidiabetic drugs such as metformin, acarbose and troglitazone, or antiobesity agents such as orlistat. Arterial hypertension, a clinical entity in which insulin resistance is common, is strongly associated with type 2 diabetes and may precede the disease by several years. While antihypertensive agents such as diuretics or beta-adrenoceptor antagonists may worsen insulin resistance and impair glucose tolerance, newer antihypertensive agents exert neutral or even slightly positive metabolic effects. Numerous clinical trials have investigated the effects of ACE inhibitors or angiotensin II receptor antagonists (ARAs) on insulin sensitivity in hypertensive patients, with or without diabetes, with no consistent results. Almost half of the studies with ACE inhibitors in hypertensive nondiabetic individuals demonstrated a slight but significant increase in insulin sensitivity as assessed by insulin-stimulated glucose disposal during a euglycaemic hyperinsulinaemic clamp, while the other half failed to reveal any significant change. The effects of ARAs on insulin sensitivity are neutral in most studies. Mechanisms of improvement of glucose tolerance and insulin sensitivity through the inhibition of the renin-angiotensin system (RAS) are complex. They may include improvement of blood flow and microcirculation in skeletal muscles and, thereby, enhancement of insulin and glucose delivery to the insulin-sensitive tissues, facilitating insulin signalling at the cellular level and improvement of insulin secretion by the beta cells. Six recent large-scale clinical studies reported a remarkably consistent reduction in the incidence of type 2 diabetes in hypertensive patients treated with either ACE inhibitors or ARAs for 3-6 years, compared with a thiazide diuretic, beta-adrenoceptor antagonist, the calcium channel antagonist amlodipine or even placebo. The relative risk reduction averaged 14% (p = 0.034) in the CAPPP (Captopril Prevention Project) with captopril compared with a thiazide or beta1-adrenoceptor antagonist, 34% (p < 0.001) in the HOPE (Heart Outcomes Prevention Evaluation) study with ramipril compared with placebo, 30% (p < 0.001) in the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) with lisinopril compared with chlortalidone, 25% (p < 0.001) in the LIFE (Losartan Intervention For Endpoint reduction in hypertension study) with losartan compared with atenolol, and 25% (p = 0.09) in the SCOPE (Study on Cognition and Prognosis in the Elderly) with candesartan cilexetil compared with placebo, and 23% (p < 0.0001) in the VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial with valsartan compared with amlodipine. All these studies considered the development of diabetes as a secondary endpoint, except the HOPE trial where it was a post hoc analysis. These encouraging observations led to the initiation of two large, prospective, placebo-controlled randomised clinical trials whose primary outcome is the prevention of type 2 diabetes: the DREAM (Diabetes REduction Approaches with ramipril and rosiglitazone Medications) trial with the ACE inhibitor ramipril and the NAVIGATOR (Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research) trial with the ARA valsartan. Finally, ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) will also investigate as a secondary endpoint whether it is possible to prevent the development of type 2 diabetes by blocking the RAS with either an ACE inhibitor or an ARA or a combination of both. Thus, the recent consistent observations of a 14-34% reduction of the development of diabetes in hypertensive patients receiving ACE inhibitors or ARAs are exciting. From a theoretical point of view, they emphasise that there are many aspects of the pathogenesis, prevention and treatment of type 2 diabetes that still need to be uncovered. From a practical point of view, they may offer a new strategy to reduce the ongoing epidemic and burden of type 2 diabetes.

Overview

Integrity signals

Registry

Crossref · 10.2165/00003495-200464220-00004

Cites

222 of 222 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 222 references

Research works printed but not linked: 13

  1. McFarlane, 2001, J Clin Endocrinol Metab, 86, 713
  2. Medalie, 1975, Arch Intern Med, 135, 811, 10.1001/archinte.1975.00330060055007 · DOI · Paper page
  3. 1994, World Health Organ Tech Rep Ser, 844, 1
  4. Scheen, 2002, Med Hyg, 60, 1480
  5. Paquot, 1995, Med Hyg, 53, 1633
  6. Scheen, 2001, Diabetes Metab, 27, 193
  7. Lefebvre, 1995, Clin Invest Med, 18, 340
  8. Tiret, 1992, Am J Hum Genet, 51, 197
  9. Petrie, 2000, J Clin Endocrinol Metab, 85, 1882
  10. Paolisso, 1995, J Hum Hypertens, 9, 541
  11. Paolisso, 1992, J Hum Hypertens, 6, 175
  12. Richey, 1999, Am J Physiol, 277, E920
  13. Henriksen, 1999, Am J Physiol, 277, R332

Cited by

Sorted by citations

Items 201–291 of 291

Related

See all

Metadata

Authors
Scheen, A. J.
Affiliations
University of Liège (BE)
Corresponding author
Scheen, Andr?? J
Venue
Drugs
Publisher
Springer Science and Business Media LLC
Published
2004
Volume
64
Issue
22
Pages
2537-2565
ISSN
0012-6667 (ISSN-L)
DOI
10.2165/00003495-200464220-00004
OpenAlex
W1561463821
Cited by
293
References
222
Citations by year
2025: 3 · 2024: 6 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 7 · 2019: 4 · 2018: 9 · 2017: 7 · 2016: 9 · 2015: 6 · 2014: 12 · 2013: 8 · 2012: 11
FWCI
6.24
Type
journal article
Language
en
Open access
closed
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
  • Open Repository and Bibliography (University of Liège) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords
type 2 diabetes prevention, renin-angiotensin system, ACE inhibitors, angiotensin receptor blockers, hypertension, insulin sensitivity, glucose tolerance, captopril, ramipril, amlodipine, thiazide diuretics, beta-blockers, insulin resistance, beta-cell function, microcirculation, hope
MeSH terms
Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Humans, Hypertension, Insulin Resistance, Renin-Angiotensin System, Randomized Controlled Trials as Topic, Angiotensin II Type 2 Receptor Blockers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review